Having this article—the first scientific retrospective analysis of Cenegenics-treated patients—featured on the title page of the Journal of Geriatric Cardiology underlines the importance and interest of testosterone therapy for older men.
Las Vegas, NV (PRWEB) January 20, 2012
The recent Journal of Geriatric Cardiology (Volume 8, issue 4) featured a retrospective data analysis study of Cenegenics’ commercially available program for middle-aged, obese men that revealed a surprising reduction in cardio risk factors, announced Cenegenics® Medical Institute. The study—a collaborative effort with Dr. Ernst R. von Schwarz, Chief Medical Officer of the Heart Institute of Southern California and professor of medicine at UCLA’s David Geffen School of Medicine—centered on Cenegenics’ physician-supervised program encompassing nutrition, exercise and testosterone replacement therapy.
According to Cenegenics, the study is the first reporting demonstrating the beneficial effects of a combined, commercially available nutrition/exercise program with testosterone replacement in men who had a clinical indication. Although it is not a randomized controlled prospective study, the findings from the non-randomized study revealed highly significant changes. However, the global leader says further controlled prospective studies should be performed to confirm this initial data.
“Having this article—the first scientific retrospective analysis of Cenegenics-treated patients—featured on the title page of the open access Journal of Geriatric Cardiology underlines the importance and interest among a large readership on the topic of testosterone therapy for older men,” Schwarz said.
Male patients fell within a median age of 52 (± 7.8 years). Over a 6- to 18-month follow up, participants showed a significant reduction in weight and body fat as well as fasting glucose levels, lipids and total cholesterol levels—all are major risk factors for cardiovascular disease. None of the participants had diabetes, hypertension or cardiovascular disease.
The physician-supervised program encompassed low-glycemic nutrition, interval training and weight training as well as testosterone therapy, with no adverse effects. The statistically significant findings are prompting Cenegenics to consider broadening their parameters, reaching out to high-risk patients who aren’t ill yet, but who could benefit from their risk-reduction program.
“This study shows we can markedly reduce risk factors for the development of chronic illness, such as atherosclerosis . . . and that it takes more than a wellness program to optimize health. From its 1997 beginnings, Cenegenics’ medical system has been based on balance—nutrition/nutraceuticals, exercise and hormone optimization as well as ongoing physician follow-ups. We’re in the business of taking medicine to new directions and heights, not waiting for people to get sick before they’re treated.Our 14- year experience shows the Cenegenics program makes a difference,” Dr. Robert D. Willix, Jr. said.
Willix is Cenegenics’ Chief Medical Officer and CEO/Chief Medical Officer of Cenegenics Boca Raton.
For more information about Cenegenics, please visit them online, where you can register for quick access to the online Cenegenics Healthy Aging Kit: informative Guide to Healthy Aging, Executive Summary and media excerpts.
Physicians can learn more about age management medicine directly by calling Cenegenics: Dr. Michael Resnick at 702.953.1574 or Dr. Tim Patel at 702.953.1577. Or visit Cenegenics' physician site to learn more about Cenegenics’ highly regarded, CME-accredited Physician Training & Certification in Age Management Medicine program.
To schedule an interview, please contact Ann Castro, Cenegenics Director of Media Relations: 702.953.1588.
About Ernst R. von Schwarz, MD, PhD, FESC, FACC, FSCAI
Dr. Ernst R. von Schwarz is board certified in internal medicine by the American Board of Internal Medicine and in cardiology/cardiovascular diseases by the American Board of Internal Medicine. He is Chief Medical Officer of the Heart Institute of Southern California and a noted professor of medicine at UCLA’s David Geffen School of Medicine. As a clinician and scientist, Schwarz has written more than 100 articles for peer-reviewed publications and has written 10 book chapters on cardiovascular medicine.
Cenegenics® Medical Institute has forged a paradigm shift in medicine, developing a proactive medical approach for optimized health hailed as “next generation medicine” and garnering worldwide media attention. Headquartered in Las Vegas, Cenegenics serves over 20,000 patients globally—2,000 are physicians and their families. Cenegenics has 19 centers with others opening in the near future: Las Vegas, Nevada; Charleston, South Carolina; Boca Raton, Florida; Dallas, Texas; Arlington, Texas; Atlanta, Georgia; Chicago, Illinois; Beverly Hills, California; Philadelphia, Pennsylvania; Washington, DC; New York City, NY; Tulsa, OK; Jacksonville, FL; Atlantic City, NJ; Houston,TX; Denver, CO; Scottsdale, AZ; Boston, MA. Cenegenics also offers CME-accredited physician training and certification opportunities in age management medicine via the nonprofit Cenegenics Education and Research Foundation (CERF).